223 related articles for article (PubMed ID: 35340661)
1. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
Jeon D; McNeel DG
Oncoimmunology; 2022; 11(1):2054758. PubMed ID: 35340661
[TBL] [Abstract][Full Text] [Related]
2. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
Jeon D; Hill E; Moseman JE; McNeel DG
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.
Wu J; Meng Z; Jiang M; Zhang E; Trippler M; Broering R; Bucchi A; Krux F; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
Immunology; 2010 Mar; 129(3):363-74. PubMed ID: 19922426
[TBL] [Abstract][Full Text] [Related]
4. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
[TBL] [Abstract][Full Text] [Related]
5. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
[TBL] [Abstract][Full Text] [Related]
6. TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8
Zahm CD; Colluru VT; McIlwain SJ; Ong IM; McNeel DG
Cancer Immunol Res; 2018 Nov; 6(11):1364-1374. PubMed ID: 30201735
[TBL] [Abstract][Full Text] [Related]
7. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes.
Zaks K; Jordan M; Guth A; Sellins K; Kedl R; Izzo A; Bosio C; Dow S
J Immunol; 2006 Jun; 176(12):7335-45. PubMed ID: 16751377
[TBL] [Abstract][Full Text] [Related]
8. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.
Loré K; Betts MR; Brenchley JM; Kuruppu J; Khojasteh S; Perfetto S; Roederer M; Seder RA; Koup RA
J Immunol; 2003 Oct; 171(8):4320-8. PubMed ID: 14530357
[TBL] [Abstract][Full Text] [Related]
10. Combination of TLR1/2 and TLR3 ligands enhances CD4(+) T cell longevity and antibody responses by modulating type I IFN production.
Lee BR; Jeong SK; Ahn BC; Lee BJ; Shin SJ; Yum JS; Ha SJ
Sci Rep; 2016 Sep; 6():32526. PubMed ID: 27580796
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.
Tada H; Aiba S; Shibata K; Ohteki T; Takada H
Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.
Babikr F; Wan J; Xu A; Wu Z; Ahmed S; Freywald A; Chibbar R; Wu Y; Moser M; Groot G; Zhang W; Zhang B; Xiang J
Cell Mol Immunol; 2021 Dec; 18(12):2632-2647. PubMed ID: 34782757
[TBL] [Abstract][Full Text] [Related]
13. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.
Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A
J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I
J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554
[TBL] [Abstract][Full Text] [Related]
15. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
16. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro.
Liu J; Jiang M; Ma Z; Dietze KK; Zelinskyy G; Yang D; Dittmer U; Schlaak JF; Roggendorf M; Lu M
J Immunol; 2013 Dec; 191(12):6178-90. PubMed ID: 24227786
[TBL] [Abstract][Full Text] [Related]
17. Epigenomics of conventional type-I dendritic cells depicted preferential control of TLR9 versus TLR3 response by NCoR1 through differential IRF3 activation.
Mishra GP; Jha A; Ahad A; Sen K; Sen A; Podder S; Prusty S; Biswas VK; Gupta B; Raghav SK
Cell Mol Life Sci; 2022 Jul; 79(8):429. PubMed ID: 35849243
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A.
Zanvit P; Tichopád A; Havlíčková M; Novotná O; Jirkovská M; Kološtová K; Cechová D; Julák J; Sterzl I; Prokešová L
Immunol Lett; 2010 Nov; 134(1):26-34. PubMed ID: 20709105
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
20. A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.
Rudra JS; Banasik BN; Milligan GN
Vaccine; 2018 Jan; 36(4):438-441. PubMed ID: 29248267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
